La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Dentsply Sirona a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Dentsply Sirona..

Dentsply Sirona (NASDAQ:XRAY) Azioni, Catena delle Opzioni

DENTSPLY SIRONA INC

Dentsply Sirona

Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (manufactured dental consumables and lab products) and Sirona Dental Systems (manufactured technologically-advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology and equipment through third-party distributors and the remaining portfolio is either sold to labs and offices through the firm's salesforce or directly to consumers (such as Byte clear aligner).

Pfizer logo on building

News

Dividends

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

XRAY

I titoli a dividendo nel settore sanitario possono essere un&#39;opzione interessante per gli investitori che cercano un reddito regolare.

Titoli a dividendo nel settore sanitario: quali sono i migliori?

Rueil-malmaison,,France,-,August,13,,2023:,French,Headquarters,Of,Bristol-myers

VTRS

Rendimento elevato e affidabilità: come trovare le aziende del settore farmaceutico e sanitario più promettenti per il tuo portafoglio.

Dividendi stabili e rendimenti alti: le azioni del settore sanitario da comprare ora

Dividend Yield

In un mercato in continua evoluzione, i titoli a dividendo rappresentano un&#39;ancora di stabilità per molti investitori.

In cerca di dividendi? 3 azioni sanitarie dall&#39;elevato rendimento

Dentsply Sirona Inc

Management

Dentsply Sirona Names Matthew E. Garth As CFO Effective May 30, 2025

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 7.47%</li>
<li>UBS analyst Trung Huynh maintained a Neutral rating and raised the price target from $24 to $25 on April 30, 2025. This analyst has an accuracy rate of 67%.</li>
<li>Guggenheim analyst Vamil Divan reiterated a Buy rating on March 18, 2025. This analyst has an accuracy rate of 72%.</li>
<li>Recent News: Pfizer announced Monday it has secured exclusive global rights, excluding China, to 3SBio Inc.'s bispecific antibody SSGJ-707 in a deal potentially worth up to $6 billion.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest PFE <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0522">news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0522"><img loading="lazy" decoding="async" width="891" height="832" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22050725/image-280.png" alt="" class="wp-image-924044" style="width:531px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22050725/image-280.png 891w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22050725/image-280-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22050725/image-280-768x717.png 768w" sizes="(max-width: 891px) 100vw, 891px" /></a></figure>
<h3 class="wp-block-heading">Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 4.21%</li>
<li>Citigroup analyst Andrew Baum downgraded the stock from Buy to Neutral and cut the price target from $115 to $84 on May 14, 2025. This analyst has an accuracy rate of 69%.</li>
<li>Guggenheim analyst Vamil Divan reiterated a Buy rating with a price target of $115 on April 17, 2025. This analyst has an accuracy rate of 72%.</li>
<li>Recent News: On May 19, Merck and Daiichi Sankyo started Phase 3 trial for Esophageal Cancer Drug.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest MRK <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0522">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0522"><img loading="lazy" decoding="async" width="900" height="827" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22050803/image-281.png" alt="" class="wp-image-924046" style="width:545px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22050803/image-281.png 900w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22050803/image-281-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22050803/image-281-768x706.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></a></figure>
<h3 class="wp-block-heading">DENTSPLY SIRONA Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 4.04%</li>
<li>UBS analyst Kevin Caliendo maintained a Buy rating and cut the price target from $27 to $25 on May 9, 2025. This analyst has an accuracy rate of 71%.</li>
<li>Mizuho analyst Steven Valiquette maintained a Neutral rating and slashed the price target from $21 to $18 on March 13, 2025. This analyst has an accuracy rate of 61%.</li>
<li>Recent News: On May 8, DENTSPLY SIRONA reported better-than-expected first-quarter financial results and raised its FY25 sales guidance above estimates.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0522">XRAY news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0522"><img loading="lazy" decoding="async" width="901" height="822" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22050834/image-282.png" alt="" class="wp-image-924050" style="width:590px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22050834/image-282.png 901w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22050834/image-282-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22050834/image-282-768x701.png 768w" sizes="(max-width: 901px) 100vw, 901px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45540545/jim-cramer-recommends-not-buying-mosaic-doesnt-like-this-industrial-stock">Jim Cramer Recommends Not Buying Mosaic, Doesn&#8217;t Like This Industrial Stock</a> </li>
</ul>
Photo via Shutterstock

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

Analysts' ratings for Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) over the last quarter vary from bullish to bearish, as provided by 9 analysts.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Dentsply Sirona, revealing an average target of $20.22, a high estimate of $25.00, and a low estimate of $16.00. A 9.65% drop is evident in the current average compared to the previous average price target of $22.38. 
<img src="https://www.benzinga.com/files/images/story/2025/1747058481_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Dentsply Sirona. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$21.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$25.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Steven Valiquette</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Vik Chopra</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$19.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$20.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Jeffrey Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$20.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$23.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Vik Chopra</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Dentsply Sirona. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Dentsply Sirona compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Dentsply Sirona's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Dentsply Sirona's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/XRAY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Dentsply Sirona analyst ratings.</a>
<h2>Discovering Dentsply Sirona: A Closer Look</h2>
Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (manufactured dental consumables and lab products) and Sirona Dental Systems (manufactured technologically-advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology and equipment through third-party distributors and the remaining portfolio is either sold to labs and offices through the firm's salesforce or directly to consumers (such as Byte clear aligner).
<h3>Financial Insights: Dentsply Sirona</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Negative Revenue Trend: Examining Dentsply Sirona's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -7.76% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Dentsply Sirona's net margin excels beyond industry benchmarks, reaching 2.28%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Dentsply Sirona's ROE excels beyond industry benchmarks, reaching 1.01%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Dentsply Sirona's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.34%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.21, caution is advised due to increased financial risk.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Dentsply Sirona: 9 Analysts Share Their Views

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Guggenheim cut Intellia Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) price target from $55 to $45. Guggenheim analyst Debjit Chattopadhyay maintained a Buy rating. Intellia Therapeutics shares closed at $8.12 on Friday. <a href="https://www.benzinga.com/quote/NTLA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Canaccord Genuity raised the price target for Nexxen International Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXN#NASDAQ">NEXN</a>) from $12 to $14. Canaccord Genuity analyst Maria Ripps maintained a Buy rating. Nexxen International shares closed at $11.54 on Friday. <a href="https://www.benzinga.com/quote/NEXN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs slashed Warner Music Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WMG#NASDAQ">WMG</a>) price target from $35 to $28. Goldman Sachs analyst Stephen Laszczyk downgraded the stock from Buy to Neutral. Warner Music shares closed at $27.36 on Friday. See how other analysts <a href="https://www.benzinga.com/quote/WMG/analyst-ratings">view this stock</a>.</li>
<li>HC Wainwright &amp; Co slashed the price target for Ocugen, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCGN#NASDAQ">OCGN</a>) from $8 to $7. HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintained a Buy rating. Ocugen shares closed at $0.67 on Friday. <a href="https://www.benzinga.com/quote/OCGN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham slashed the price target for Vir Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIR#NASDAQ">VIR</a>) from $19 to $14. Needham analyst Joseph Stringer maintained a Buy rating. Vir Biotechnology shares closed at $5.09 on Friday. <a href="https://www.benzinga.com/quote/VIR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan raised Teva Pharmaceutical Industries Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NASDAQ">TEVA</a>) price target from $21 to $23. JP Morgan analyst Chris Schott upgraded the stock from Neutral to Overweight. Teva Pharmaceutical shares settled at $16.93 on Friday. <a href="https://www.benzinga.com/quote/TEVA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies increased Marriott International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) price target from $226 to $303. Jefferies analyst David Katz upgraded the stock from Hold to Buy. Marriott shares closed at $257.97 on Friday. <a href="https://www.benzinga.com/quote/MAR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Barrington Research raised DENTSPLY SIRONA Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) price target from $20 to $21. Barrington Research analyst Michael Petusky maintained an Outperform rating. Dentsply Sirona shares closed at $15.81 on Friday.  <a href="https://www.benzinga.com/quote/XRAY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt slashed the price target for TeraWulf Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>) from $4.5 to $4. Rosenblatt analyst Chris Brendler maintained a Buy rating. TeraWulf shares settled at $3.01 on Friday. <a href="https://www.benzinga.com/quote/WULF/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>D. Boral Capital raised Medicus Pharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDCX#NASDAQ">MDCX</a>) price target from $14 to $27. D. Boral Capital analyst Jason Kolbert maintained a Buy rating. Medicus Pharma shares closed at $4.69 on Friday. <a href="https://www.benzinga.com/quote/MDCX/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying MAR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="612" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12094338/image-127-1024x612.png" alt="" class="wp-image-911954" style="width:591px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12094338/image-127-1024x612.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12094338/image-127-300x179.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12094338/image-127-768x459.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12094338/image-127.png 1130w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45342900/5-stock-picks-last-week-from-wall-streets-most-accurate-analysts-5">5 Stock Picks Last Week From Wall Street&#8217;s Most Accurate Analysts</a> </li>
</ul>
Photo via Shutterstock

MDCX

NEXN

NTLA

OCGN

TEVA

WULF

Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday

Barrington Research analyst Michael Petusky maintains Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) with a Outperform and raises the price target from $20 to $21.

Barrington Research Maintains Outperform on Dentsply Sirona, Raises Price Target to $21

UBS analyst Kevin Caliendo maintains Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) with a Buy and lowers the price target from $27 to $25.

UBS Maintains Buy on Dentsply Sirona, Lowers Price Target to $25

Dentsply Sirona Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) stock surged about 15% Thursday, and was on track for the biggest single-day advance since 2019 after posting earnings that topped estimates.
The company reported first-quarter 2025 adjusted earnings per share of 43 cents,&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45279156/dentsply-sirona-reports-first-quarter-2025-results" rel="noreferrer noopener">beating the street view of 30 cents</a>.
Dentsply Sirona reported sales of $879 million on Thursday, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $854.75 million</a>.
First quarter net sales decreased 7.7% (organic sales decreased 4.4%) compared to the first quarter of 2024. Foreign currency changes negatively impacted first-quarter 2025 net sales by approximately $30 million.
&#8220;In the first quarter, organic sales were roughly flat excluding the Byte sales impact, with growth in two of our three regions. Adjusted EBITDA margin expanded which primarily reflects the benefits from our transformational initiatives and internal financial discipline. We are delivering progress through customer-centric innovation, customer experience improvements, and operational efficiency, while operating in an increasingly uncertain macroeconomic environment,&#8221; said Simon Campion, President and CEO.
Adjusted EBITDA increased 4.2% to $168 million, and margin expanded from 16.8% to 19%.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44312852/needham-downgrades-dental-players-dentsply-sirona-zimvie-citing-weak-growth-outlook" rel="noreferrer noopener">Dental Players Dentsply Sirona, ZimVie Show Weak Growth Outlook: Analyst</a>
Outlook:&nbsp;&#8220;Looking forward, we are maintaining our outlook for organic sales and adjusted EPS and will continue to focus on improving what is within our control to deliver sustainable long-term performance,&#8221; Campion said.
Dentsply Sirona reaffirms adjusted earnings per share guidance of $1.80-$2.00 compared to the consensus of $1.82, reflecting F/X changes <a target="_blank" href="https://investor.dentsplysirona.com/static-files/c20e578f-29e1-40d9-8b59-e79366210e28" rel="noreferrer noopener">and</a> current tariffs.
The company raised fiscal 2025 sales guidance from $3.50 billion-$3.60 billion to $3.60 billion-$3.70 billion versus the consensus of $3.57 billion.
Organic sales are projected to decline by 2.0% to 4.0%, including a 2% <a target="_blank" href="https://www.benzinga.com/news/earnings/25/02/44011524/dentsply-sirona-q4-earnings-miss-10-sales-drop-soft-2025-outlook-and-more" rel="noreferrer noopener">impact from Byte sales</a>.
William Blair writes, &#8220;We understand noise in the P&amp;L statement is not ideal for investors, but with shares at 7 times our 2026 EPS, they are at a material discount to peers even with management executing on cost-saving initiatives to offset end-market weakness. We continue to like the risk-to-reward profile, especially with continued adoption of digital offerings that can leave Dentsply as the digital hub of accounts.&#8221;
Analyst Brandon Vazquez <a href="https://www.benzinga.com/quote/xray/analyst-ratings">maintains an Outperform rating</a>.
Price Action:&nbsp;XRAY shares are trading 12% higher at $15.32 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45292609/burger-king-parent-restaurant-brands-q1-earnings-miss-comparable-sales-drop-and-more" target="_blank" rel="noreferrer noopener">Most Of Burger King Parent Restaurant Brands Growth Came From New Restaurants; It Plans Up To $450 Million In 2025 Capex</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Earnings

Equities

Guidance

Health Care

Movers

General

Dentsply Sirona Stock Is Rallying The Most Since 2019 on Thursday – What's Driving It?

WIIM

DENTSPLY SIRONA shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 sales guidance above estimates.

2025 Outlook
The Company is maintaining its 2025 outlook for organic sales in the range of down (4.0%) to (2.0%), and adjusted EPS in the range of $1.80 to $2.00. The Company is increasing its expected reported sales to a new range of $3.60 billion to $3.70 billion due to changes in foreign exchange rates. This outlook reflects the current state of tariffs and trade policy.

Dentsply Sirona Affirms FY2025 Adj EPS Guidance of $1.80-$2.00 vs $1.82 Est; Raises FY2025 Sales Guidance from $3.50B-$3.60B to $3.60B-$3.70B vs $3.57B Est

Dentsply Sirona Q1 2025 Adj. EPS $0.43 Beats $0.30 Estimate, Sales $879.00M Beat $854.75M Estimate

AAOI

ABCL

ABEV

ACIC

ACIW

ACMR

ACTG

AFRM

AKAM

AKBA

ALGM

ALIT

ALRM

ALXO

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

AMPX

AMTX

APPN

APYX

AQMS

ARGX

ARHS

ARKO

ARLO

ASPN

ASTH

Adtalem Global Education Inc. Common Stock

ATGE

ATHM

ATUS

AUTL

AVAH

AVPT

AXGN

BAER

BBDC

BIGC

BILL

BIRD

BlackSky Technology Inc. Class A Common Stock

BKSY

BLFS

BLND

CARG

CARS

CBLL

CBUS

CCEC

CCOI

CCRD

CDTX

CION

CLAR

CLFD

CLNE

CLSK

CMPS

CMRE

CODX

COIN

COLD

COLL

COMP

CRNX

CRON

CROX

CRVS

CTEV

CTKB

CTLP

CVRX

DAVE

DCGO

DCTH

DIOD

DKNG

Earnings Scheduled For May 8, 2025

Piper Sandler analyst Jason Bednar maintains Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) with a Neutral and lowers the price target from $20 to $16.

Piper Sandler Maintains Neutral on Dentsply Sirona, Lowers Price Target to $16

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</h3>
<ul>
<li>Dividend Yield: 4.29%</li>
<li>Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating and raised the price target from $60 to $62 on Feb. 7, 2025. This analyst has an accuracy rate of 71%.</li>
<li>Citigroup analyst Andrew Baum maintained a Neutral rating and raised the price target from $60 to $65 on Jan. 28, 2025. This analyst has an accuracy rate of 71%.</li>
<li>Recent News: On March 24, Bristol Myers Squibb received positive CHMP opinion for subcutaneous formulation of Opdiv across multiple solid tumor indications.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0404">latest BMY news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0404"><img loading="lazy" decoding="async" width="906" height="817" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04045052/image-43.png" alt="" class="wp-image-857124" style="width:554px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04045052/image-43.png 906w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04045052/image-43-300x271.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04045052/image-43-768x693.png 768w" sizes="(max-width: 906px) 100vw, 906px" /></a></figure>
<h3 class="wp-block-heading">DENTSPLY SIRONA Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>)</h3>
<ul>
<li>Dividend Yield: 4.70%</li>
<li>Morgan Stanley analyst Erin Wright maintained an Overweight rating and cut the price target from $30 to $23 on Dec. 17, 2024. This analyst has an accuracy rate of 75%.</li>
<li>UBS analyst Kevin Caliendo maintained a Buy rating and cut the price target from $35 to $27 on Dec. 3, 2024. This analyst has an accuracy rate of 72%.</li>
<li>Recent News: On March 17, Dentsply Sirona named David Ferguson as Global Business Unit Leader.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest XRAY <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0404">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0404"><img loading="lazy" decoding="async" width="910" height="818" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04045120/image-1-13.png" alt="" class="wp-image-857125" style="width:555px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04045120/image-1-13.png 910w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04045120/image-1-13-300x270.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04045120/image-1-13-768x690.png 768w" sizes="(max-width: 910px) 100vw, 910px" /></a></figure>
<h3 class="wp-block-heading">Viatris Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>)</h3>
<ul>
<li>Dividend Yield: 5.88%</li>
<li>Piper Sandler analyst David Amsellem reiterated a Neutral rating and raised the price target from $13 to $14 on Dec. 6, 2024. This analyst has an accuracy rate of 73%.</li>
<li>B of A Securities analyst Jason Gerberry downgraded the stock from Neutral to Underperform with a price target of $9 on Oct. 23, 2024. This analyst has an accuracy rate of 62%.</li>
<li>Recent News: Viatris will report first quarter financial results on Thursday, May 8.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest VTRS <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0404">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0404"><img loading="lazy" decoding="async" width="913" height="820" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04045307/image-1-14.png" alt="" class="wp-image-857127" style="width:526px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04045307/image-1-14.png 913w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04045307/image-1-14-300x269.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/04045307/image-1-14-768x690.png 768w" sizes="(max-width: 913px) 100vw, 913px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44641655/guess-simulations-plus-and-3-stocks-to-watch-heading-into-friday">Guess, Simulations Plus And 3 Stocks To Watch Heading Into Friday</a> </li>
</ul>
Photo via Shutterstock

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">DENTSPLY SIRONA Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>)</h3>
<ul>
<li>Dividend Yield: 4.11%</li>
<li>Mizuho analyst Steven Valiquette maintained a Neutral rating and cut the price target from $21 to $18 on March 13, 2025. This analyst has an accuracy rate of 60%.</li>
<li>Morgan Stanley analyst Erin Wright maintained an Overweight rating and cut the price target from $30 to $23 on Dec. 17, 2024. This analyst has an accuracy rate of 76%.</li>
<li>Recent News: On March 17, Dentsply Sirona named David Ferguson as Global Business Unit Leader.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">XRAY news</a>. </li>
</ul>
<figure class="wp-block-image is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/6dde7dcc-8523-415e-8b9a-848a09b31f98" alt="" style="width:509px;height:auto" /></a></figure>
<h3 class="wp-block-heading">Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</h3>
<ul>
<li>Dividend Yield: 4.06%</li>
<li>Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating and raised the price target from $60 to $62 on Feb. 7, 2025. This analyst has an accuracy rate of 73%.</li>
<li>Cantor Fitzgerald analyst Olivia Brayer maintained a Neutral rating and increased the price target from $50 to $55 on Feb. 4, 2025. This analyst has an accuracy rate of 63%.</li>
<li>Recent News: On March 14, the European Commission (EC) approved Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy..</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">BMY news</a> </li>
</ul>
<h3 class="wp-block-heading">CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</h3>
<ul>
<li>Dividend Yield: 3.97%</li>
<li>Truist Securities analyst David Macdonald maintained a Buy rating and raised the price target from $60 to $76 on Feb. 13, 2025. This analyst has an accuracy rate of 67%.</li>
<li>Leerink Partners analyst Michael Cherny upgraded the stock from Market Perform to Outperform and raised the price target from $55 to $75 on Feb. 13, 2025. This analyst has an accuracy rate of 79%.</li>
<li>Recent News: On March 20, CVS Health reported its board of directors has approved a quarterly dividend of 66.5 cents per share on the Common Stock of the Corporation.</li>
<li>Edge Stock Ratings:&nbsp;62.89 Momentum score with Value at 40.46. <a href="https://www.benzinga.com/quote/CCU" target="_blank" rel="noreferrer noopener"></a></li>
</ul>

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="470" height="188" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/24060244/image-217.png" alt="" class="wp-image-838055" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/24060244/image-217.png 470w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/24060244/image-217-300x120.png 300w" sizes="(max-width: 470px) 100vw, 470px" /></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Want Edge Stock Rankings on this stock?&nbsp;<a href="https://www.benzinga.com/quote/CELH" target="_blank" rel="noreferrer noopener">Become an Edge subscriber here</a>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44434941/how-to-earn-500-a-month-from-kb-home-stock-ahead-of-q1-earnings">How To Earn $500 A Month From KB Home Stock Ahead Of Q1 Earnings</a></li>
</ul>
Photo: Shutterstock

Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) and ZimVie Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZIMV#NASDAQ">ZIMV</a>) show below-market growth and have no meaningful upside, <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">according Needham analysts</a>.
What Happened: Needham downgraded the two dental companies to Hold.
ZimVie reported adjusted EPS of 27 cents, beating the consensus of 26 cents. The company&#8217;s sales of $111.52 million fell below the <a href="https://www.benzinga.com/pressreleases/25/02/g43989465/zimvie-reports-fourth-quarter-and-full-year-2024-financial-results" target="_blank" rel="noreferrer noopener">consensus of $113.4 million</a>.
Dentsply Sirona, meanwhile, reported fourth-quarter adjusted earnings per share of 26 cents. It missed the street view of 43 cents. Quarterly sales of $905 million (down 10.6% year over year) missed the analyst consensus estimate of $920.56 million. Organic Sales <a href="https://www.benzinga.com/news/earnings/25/02/44011524/dentsply-sirona-q4-earnings-miss-10-sales-drop-soft-2025-outlook-and-more" target="_blank" rel="noreferrer noopener">fell 10.7% year over year</a>.
In February, consumer sentiment in the U.S. declined. The University of Michigan&#8217;s Consumer Sentiment Index <a href="https://www.benzinga.com/general/market-summary/25/02/43889033/consumer-sentiment-drops-10-unitedhealth-under-investigation-whats-driving-markets-friday" target="_blank" rel="noreferrer noopener">dropped to 64.7 from 71.1</a> in January (initially reported as 73.2). Dental firms&#8217; management looks at consumer sentiment to gauge consumers&#8217; willingness to spend on dental care.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/02/44011524/dentsply-sirona-q4-earnings-miss-10-sales-drop-soft-2025-outlook-and-more" rel="noreferrer noopener">Dentsply Sirona Q4: Earnings Miss, 10% Sales Drop, Soft 2025 Outlook And More</a>
Why It Matters: Interest rates play a key role because major purchases are usually financed. While some rate cuts may start around midyear, high interest rates will likely continue to weigh on capital demand.
Adding to these challenges, ongoing staffing shortages in the provider market could limit capacity even if patient demand increases.
Analyst David Saxon writes that Dentsply Sirona continues to lose market share. The company is overexposed to equipment, he argues. That has been one of the softest product categories in dentistry, he adds. Low-cost/value launches from competitors have created pricing pressure, and interest rates remain a headwind to demand.
ZimVie is also losing implant market share — 60% of its portfolio. The company has upcoming initiatives meant to drive improved execution. The analyst expects it will take time for these to get ZimVie&#8217;s growth to be at or above the market&#8217;s growth.
Needham also comments on tariff exposure on another dental player, Align Technology, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>).
The clear aligners and iTero sleeves are covered under the USMCA (US-Mexico-Canada Agreement) and are exempt from tariffs until April 2025
Price Action: ALGN stock is down 3.59% at $158.66. XRAY stock is down 2.28% at $14.98. ZIMV stock is down 6.64% at $11.81 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44306214/gm-and-pge-team-up-to-let-evs-power-homes-offer-up-to-4500-in-energy-incentives" target="_blank" rel="noreferrer noopener">GM And PG&amp;E Team Up To Let EVs Power Homes, Offer Up To $4,500 In Energy Incentives</a></li>
</ul>

Downgrades

ALGN

ZIMV

Dental Players Dentsply Sirona, ZimVie Show Weak Growth Outlook: Analyst

Mizuho analyst Steven Valiquette maintains Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) with a Neutral and lowers the price target from $21 to $18.

Mizuho Maintains Neutral on Dentsply Sirona, Lowers Price Target to $18

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>B of A Securities analyst Brad Sills downgraded the rating for UiPath Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) from Neutral to Underperform and lowered the price target from $18 to $10. UiPath shares closed at $11.83 on Wednesday. <a href="https://www.benzinga.com/quote/path/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Ryan Kenny downgraded Moelis &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MC#NYSE">MC</a>) from Overweight to Underweight and lowered the price target from $100 to $70. Moelis shares closed at $60.09 on Wednesday. <a href="https://www.benzinga.com/quote/mc/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham analyst David Saxon downgraded the rating for DENTSPLY SIRONA Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) from Buy to Hold. Dentsply Sirona shares closed at $15.33 on Wednesday. <a href="https://www.benzinga.com/quote/XRAY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities analyst Ki Bin Kim downgraded Federal Realty Investment Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRT#NYSE">FRT</a>) from Buy to Hold and lowered the price target from $114 to $105. Federal Realty Investment shares closed at $97.12 on Wednesday. <a href="https://www.benzinga.com/quote/FRT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham analyst David Saxon downgraded the rating for ZimVie Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZIMV#NASDAQ">ZIMV</a>) from Buy to Hold. ZimVie shares closed at $12.65 on Wednesday. <a href="https://www.benzinga.com/quote/ZIMV/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying PATH stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="595" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/13080714/image-103-1024x595.png" alt="" class="wp-image-822803" style="width:585px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/13080714/image-103-1024x595.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/13080714/image-103-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/13080714/image-103-768x446.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/13080714/image-103.png 1121w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44295828/adobe-intel-and-3-stocks-to-watch-heading-into-thursday">Adobe, Intel And 3 Stocks To Watch Heading Into Thursday</a></li>
</ul>

PATH

This UiPath Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday

Needham analyst David Saxon downgrades Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) from Buy to Hold.

Needham Downgrades Dentsply Sirona to Hold

Wells Fargo analyst Vik Chopra maintains Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) with a Equal-Weight and lowers the price target from $20 to $19.

Wells Fargo Maintains Equal-Weight on Dentsply Sirona, Lowers Price Target to $19

Barrington Research analyst Michael Petusky maintains Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) with a Outperform and lowers the price target from $24 to $20.

Barrington Research Maintains Outperform on Dentsply Sirona, Lowers Price Target to $20

Press Releases

Dentsply Sirona Initiates Review of Strategic Alternatives for Wellspect Healthcare

Legal

DENTSPLY ALERT: Bragar Eagel & Squire, P.C. is Investigating DENTSPLY SIRONA Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Dentsply Sirona Reports Fourth Quarter and Full Year 2024 Results, Provides Full Year 2025 Outlook

Dentsply Sirona to Participate in the Leerink Partners Global Healthcare Conference 2025

Comments

Dentsply Sirona

Dentsply Sirona (XRAY) Opzioni

Dentsply Sirona (NASDAQ:XRAY) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO